Contrast Media Injectors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Contrast Media Injectors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The contrast media injectors market is expected to grow from USD 1,558.09 million in 2021, at a CAGR of 6.22% during the forecast period.

The COVID-19 pandemic has had a devastating impact on the global population’s health and a significant economic impact on most countries. The volume of imaging cases in many radiology departments dropped dramatically. The COVID-19 outbreak impacted patients’ access to healthcare facilities as the pandemic forced them to wait for lifesaving imaging procedures. The pandemic also increased the waiting time for patients to have their imaging done. According to an article published by the Radiology Society of North America in April 2020, the COVID-19 pandemic profoundly impacted radiology practices across the country.

Similarly, as per the article published in the RSNA Journal in 2020, by Joseph J. Cavallo, radiology practices should anticipate 50–70% decreases in imaging volume that will last a minimum of 3–4 months, depending on the location of practice and the severity of the COVID-19 pandemic in each region. The demand for contrast injectors will be primarily determined by the volume of diagnostic imaging and the number of CT and MRI machines installed. The demand for diagnostic imaging is expected to return to normalcy in a few months, leading to a recovery in the contrast media injectors market.

The major factors attributing to the growth of the contrast media injectors market are increasing demand for minimally invasive surgeries, technological advancements, and an increasing number of regulatory approvals. Several advancements in contrast media injector technology have been made to reduce contrast media waste and automate data collection regarding the dose received by a patient. For example, the automated injector systems precisely collect the amount of contrast media used. Vendors are offering personalized doses for patients using the information pulled from EMR or PACS. One such advancement in reducing contrast media waste is syringeless injectors.

According to the World Health Organization (WHO) 2021, cardiovascular diseases (CVDs) are the number one cause of death globally. An estimated 17.9 million each year suffer from cardiovascular diseases. Four out of five cardiovascular deaths are due to strokes and heart attacks, and one-third of deaths occur prematurely in people under 70 years.

Most companies are developing innovative products to reduce contrast media waste and gain a competitive advantage. Bracco has developed smart syringeless injectors, which can use every drop of contrast loaded into the system for maximum economy. Smart injectors record the amount injected and the imaging protocol used and send the information to the PACS. These constant technological advancements in contrast media injector technology are expected to boost the market during the forecast period.

CT injectors are expected to grow positively as the usage of CT systems has been increasing over the past few years. These CT systems use a dual-head injector with two syringes for initial and follow-up contrast doses during imaging. There has been constant R&D activity by major academic centers and pharmaceutical companies to develop protocols, which help CT users with the advanced capabilities of newer imaging systems. The integration of IT and contrast media dose management are prospective growth factors for the market during the forecast period.

Manufacturers of CT and automated contrast injectors are partnering to better integrate their systems, including contrast dose tracking. Mallinckrodt launched an OptiSync data management system designed to collect and analyze radiology data when a patient undergoes a contrast-media-enhanced CT imaging procedure.

To remain competitive in the market, major players are gradually implementing various strategies, such as collaborative initiatives. For example, Ulrich Medical, a German medical technology company, presented a version of its CT motion contrast media injector designed for the American market at the RSNA in Chicago in May 2020. It was approved by the FDA and marketed in collaboration with GE Healthcare.

All such factors are expected to boost the market’s growth positively over the forecast period.

North America is expected to dominate the overall market during the forecast period, primarily due to the increasing preference for minimally invasive procedures and the increasing prevalence of chronic diseases due to changing lifestyles. United States holds the largest market share in the region.

According to the Centers for Disease Control and Prevention 2021, chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in United States. They also contribute to USD 3.8 trillion in annual health care costs. Six in 10 adults in the country have a chronic disease, and four in every 10 adults have two or more chronic diseases. Therefore, the high incidence rate of chronic diseases in the country is driving the growth of the contrast media injectors market in United States.

Additionally, as per Heart Disease & Stroke Statistical Fact Sheet 2020, a minimum of 40,000 infants are expected to be affected each year by congenital heart defects in United States. About 25% or 2.4 (per 1,000 live births) require treatment in the first year of an infant’s life.

Technological advancements in contrast media injector devices, increasing expenditure by key players, and rising regulatory approvals are also boosting the growth of the contrast media injectors market in North America.

The contrast media injectors market is consolidated, competitive, and consists of a few major players. In terms of market share, few major players currently dominate the market. With the increasing technological advancements, high prevalence of diseases, and increasing usage of minimally invasive surgeries, more companies are expected to enter the market in the coming years. Major players in the market are Bracco Group, GE Healthcare, Bayer HealthCare, Medtron AG, and Ulrich GmbH & Co. KG.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support